Can you take Bitolterol with Dolasetron?

Dolasetron has a major potential interaction with Abnormal Electrocardiogram.

Dolasetron may cause acute but usually reversible and self-limiting interval changes in the electrocardiogram, including PR, QTc and JT prolongation and QRS widening. The incidence and severity of these changes are related to serum levels of the active metabolite, hydrodolasetron. Cardiovascular morbidity such as heart block and cardiac arrhythmias may occur rarely. Therapy with dolasetron should be administered cautiously in patients with or predisposed to prolongation of cardiac conduction intervals. Risk factors include hypokalemia; hypomagnesemia; use of diuretics that may induce electrolyte abnormalities; use of antiarrhythmic agents or other drugs that may cause QTc prolongation; cumulative high-dose anthracycline therapy; significant bradycardia; congestive heart failure; myocardial ischemia; and atrial fibrillation.

Dolasetron has a major potential interaction with Arrhythmia.

Dolasetron may cause acute but usually reversible and self-limiting interval changes in the electrocardiogram, including PR, QTc and JT prolongation and QRS widening. The incidence and severity of these changes are related to serum levels of the active metabolite, hydrodolasetron. Cardiovascular morbidity such as heart block and cardiac arrhythmias may occur rarely. Therapy with dolasetron should be administered cautiously in patients with or predisposed to prolongation of cardiac conduction intervals. Risk factors include hypokalemia; hypomagnesemia; use of diuretics that may induce electrolyte abnormalities; use of antiarrhythmic agents or other drugs that may cause QTc prolongation; cumulative high-dose anthracycline therapy; significant bradycardia; congestive heart failure; myocardial ischemia; and atrial fibrillation.

Bitolterol has a moderate potential interaction with Diabetes Mellitus.

Adrenergic bronchodilators may cause increases in blood glucose concentrations. These effects are usually transient and slight, but may be significant with dosages higher than those normally recommended. Large doses of IV albuterol (not commercially available in the U.S.) and terbutaline sulfate have been reported to cause exacerbation of preexisting diabetes mellitus and ketoacidosis. Therapy with adrenergic bronchodilators should be administered cautiously in patients with diabetes mellitus. Closer monitoring of blood glucose concentrations may be appropriate. Systemic adverse effects are minimized, but not abolished, by administration of these agents via oral inhalation.

Dolasetron has a major potential interaction with Electrolyte Abnormalities.

Dolasetron may cause acute but usually reversible and self-limiting interval changes in the electrocardiogram, including PR, QTc and JT prolongation and QRS widening. The incidence and severity of these changes are related to serum levels of the active metabolite, hydrodolasetron. Cardiovascular morbidity such as heart block and cardiac arrhythmias may occur rarely. Therapy with dolasetron should be administered cautiously in patients with or predisposed to prolongation of cardiac conduction intervals. Risk factors include hypokalemia; hypomagnesemia; use of diuretics that may induce electrolyte abnormalities; use of antiarrhythmic agents or other drugs that may cause QTc prolongation; cumulative high-dose anthracycline therapy; significant bradycardia; congestive heart failure; myocardial ischemia; and atrial fibrillation.

Bitolterol has a moderate potential interaction with Heart Disease.

Adrenergic bronchodilators can stimulate cardiovascular beta- 1 and beta- 2 receptors, resulting in adverse effects such as tachycardia, palpitation, peripheral vasodilation, blood pressure changes, and ECG changes (e.g., flattening of the T wave; prolongation of the QT interval; ST segment depression). Direct stimulation of cardiac tissues is mediated by beta- 1 receptors and thus less likely to occur with beta-2-selective agents such as albuterol. However, beta-2-selectivity is not absolute and can be lost with larger doses. High dosages of these agents have been associated with precipitation or aggravation of angina, myocardial ischemia, and cardiac arrhythmias. Therapy with adrenergic bronchodilators should be administered cautiously in patients with sensitivity to sympathomimetic amines, hyperthyroidism, and/or underlying cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, or hypertension. The recommended dosages should not be exceeded.

Dolasetron has a major potential interaction with Heart Failure.

Dolasetron may cause acute but usually reversible and self-limiting interval changes in the electrocardiogram, including PR, QTc and JT prolongation and QRS widening. The incidence and severity of these changes are related to serum levels of the active metabolite, hydrodolasetron. Cardiovascular morbidity such as heart block and cardiac arrhythmias may occur rarely. Therapy with dolasetron should be administered cautiously in patients with or predisposed to prolongation of cardiac conduction intervals. Risk factors include hypokalemia; hypomagnesemia; use of diuretics that may induce electrolyte abnormalities; use of antiarrhythmic agents or other drugs that may cause QTc prolongation; cumulative high-dose anthracycline therapy; significant bradycardia; congestive heart failure; myocardial ischemia; and atrial fibrillation.

Bitolterol has a moderate potential interaction with High Blood Pressure.

Adrenergic bronchodilators can stimulate cardiovascular beta- 1 and beta- 2 receptors, resulting in adverse effects such as tachycardia, palpitation, peripheral vasodilation, blood pressure changes, and ECG changes (e.g., flattening of the T wave; prolongation of the QT interval; ST segment depression). Direct stimulation of cardiac tissues is mediated by beta- 1 receptors and thus less likely to occur with beta-2-selective agents such as albuterol. However, beta-2-selectivity is not absolute and can be lost with larger doses. High dosages of these agents have been associated with precipitation or aggravation of angina, myocardial ischemia, and cardiac arrhythmias. Therapy with adrenergic bronchodilators should be administered cautiously in patients with sensitivity to sympathomimetic amines, hyperthyroidism, and/or underlying cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, or hypertension. The recommended dosages should not be exceeded.

Bitolterol has a moderate potential interaction with Hyperthyroidism.

Adrenergic bronchodilators can stimulate cardiovascular beta- 1 and beta- 2 receptors, resulting in adverse effects such as tachycardia, palpitation, peripheral vasodilation, blood pressure changes, and ECG changes (e.g., flattening of the T wave; prolongation of the QT interval; ST segment depression). Direct stimulation of cardiac tissues is mediated by beta- 1 receptors and thus less likely to occur with beta-2-selective agents such as albuterol. However, beta-2-selectivity is not absolute and can be lost with larger doses. High dosages of these agents have been associated with precipitation or aggravation of angina, myocardial ischemia, and cardiac arrhythmias. Therapy with adrenergic bronchodilators should be administered cautiously in patients with sensitivity to sympathomimetic amines, hyperthyroidism, and/or underlying cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, or hypertension. The recommended dosages should not be exceeded.

Dolasetron has a major potential interaction with Hypokalemia.

Dolasetron may cause acute but usually reversible and self-limiting interval changes in the electrocardiogram, including PR, QTc and JT prolongation and QRS widening. The incidence and severity of these changes are related to serum levels of the active metabolite, hydrodolasetron. Cardiovascular morbidity such as heart block and cardiac arrhythmias may occur rarely. Therapy with dolasetron should be administered cautiously in patients with or predisposed to prolongation of cardiac conduction intervals. Risk factors include hypokalemia; hypomagnesemia; use of diuretics that may induce electrolyte abnormalities; use of antiarrhythmic agents or other drugs that may cause QTc prolongation; cumulative high-dose anthracycline therapy; significant bradycardia; congestive heart failure; myocardial ischemia; and atrial fibrillation.

Bitolterol has a moderate potential interaction with Hypokalemia.

Adrenergic bronchodilators may cause decreases in serum potassium concentrations, primarily when given by nebulization or intravenous administration. Although this effect is usually transient and does not require supplementation, clinically significant hypokalemia may occur in some patients, with the potential to induce cardiovascular adverse effects. The relevance of these observations to oral or oral aerosol/powder for inhalation therapy is unknown. Therapy with adrenergic bronchodilators should be administered cautiously in patients with or predisposed to hypokalemia.

Dolasetron has a major potential interaction with Ischemic Heart Disease.

Dolasetron may cause acute but usually reversible and self-limiting interval changes in the electrocardiogram, including PR, QTc and JT prolongation and QRS widening. The incidence and severity of these changes are related to serum levels of the active metabolite, hydrodolasetron. Cardiovascular morbidity such as heart block and cardiac arrhythmias may occur rarely. Therapy with dolasetron should be administered cautiously in patients with or predisposed to prolongation of cardiac conduction intervals. Risk factors include hypokalemia; hypomagnesemia; use of diuretics that may induce electrolyte abnormalities; use of antiarrhythmic agents or other drugs that may cause QTc prolongation; cumulative high-dose anthracycline therapy; significant bradycardia; congestive heart failure; myocardial ischemia; and atrial fibrillation.

Dolasetron has a major potential interaction with Magnesium Imbalance.

Dolasetron may cause acute but usually reversible and self-limiting interval changes in the electrocardiogram, including PR, QTc and JT prolongation and QRS widening. The incidence and severity of these changes are related to serum levels of the active metabolite, hydrodolasetron. Cardiovascular morbidity such as heart block and cardiac arrhythmias may occur rarely. Therapy with dolasetron should be administered cautiously in patients with or predisposed to prolongation of cardiac conduction intervals. Risk factors include hypokalemia; hypomagnesemia; use of diuretics that may induce electrolyte abnormalities; use of antiarrhythmic agents or other drugs that may cause QTc prolongation; cumulative high-dose anthracycline therapy; significant bradycardia; congestive heart failure; myocardial ischemia; and atrial fibrillation.

Bitolterol has a moderate potential interaction with Seizures.

Adrenergic bronchodilators may cause CNS stimulation. Therapy with adrenergic bronchodilators should be administered cautiously in patients with seizure disorders. Systemic adverse effects are minimized, but not abolished, by administration of these agents via oral inhalation.